Long Non-coding RNA HNF1A-AS1 Promotes Hepatocellular Carcinoma Cell Proliferation by Repressing NKD1 and P21 Expression
Overview
General Medicine
Pharmacology
Affiliations
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Recent evidences have demonstrated that long non-coding RNAs (lncRNAs) act as key regulators of tumor development and progression including HCC. In the study, we showed that the expression level of HNF1A-AS1 was up-regulated in HCC cell lines. Furthermore, CCK-8 cell proliferation assays and cell cycle analysis showed that HNF1A-AS1 over-expression facilitated HCC cell proliferation by promoting the cell proliferation and S-phase progression, whereas HNF1A-AS1 knockdown had the opposite effect. Western-blotting analysis revealed that knockdown of HNF1A-AS1 inhibited the cycle-relative protein cyclin-D1 and PCNA expression in HCC cells. Mechanism, RNA immunoprecipitation (RIP) and Chromatin immunoprecipitation (ChIP) assays showed that by interacting with enhancer of zeste homolog 2 (EZH2), HNF1A-AS1 promoted HCC cell proliferation by repressing the NKD1 and p21 expression. These results suggested that HNF1A-AS1 may contribute to HCC progression, which may be an effective therapeutic target for patients.
Jin J, Nguyen L, Wassef A, Sadek R, Schmitt T, Guo G Noncoding RNA. 2024; 10(2).
PMID: 38668386 PMC: 11053763. DOI: 10.3390/ncrna10020028.
Wei S, Lin L, Jiang W, Chen J, Gong G, Sui D Aging (Albany NY). 2023; 15(20):11114-11130.
PMID: 37857014 PMC: 10637826. DOI: 10.18632/aging.205105.
The HASTER lncRNA promoter is a cis-acting transcriptional stabilizer of HNF1A.
Beucher A, Miguel-Escalada I, Balboa D, De Vas M, Maestro M, Garcia-Hurtado J Nat Cell Biol. 2022; 24(10):1528-1540.
PMID: 36202974 PMC: 9586874. DOI: 10.1038/s41556-022-00996-8.
Regulatory mechanisms and potential medical applications of HNF1A-AS1 in cancers.
Zhang Y, Shi J, Luo J, Liu C, Zhu L Am J Transl Res. 2022; 14(6):4154-4168.
PMID: 35836869 PMC: 9274608.
Lin S, Xu H, Pang M, Zhou X, Pan Y, Zhang L Front Oncol. 2022; 12:831268.
PMID: 35480112 PMC: 9035874. DOI: 10.3389/fonc.2022.831268.